Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma - PubMed (original) (raw)
Comparative Study
Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma
Naomi Y Jiang et al. Cancer Epidemiol Biomarkers Prev. 2008 Jul.
Abstract
Pancreatic adenocarcinoma is one of the leading causes of cancer-related deaths in the United States. Sp1 is a sequence-specific DNA binding protein that is important in the transcription of a number of regulatory genes involved in cancer cell growth, differentiation, and metastasis. In this study, we investigated Sp1 expression in pancreatic ductal adenocarcinoma and its association with clinical outcome. We studied 42 patients with primary pancreatic adenocarcinoma. The expression of Sp1 in pancreatic adenocarcinoma was evaluated by immunohistochemical staining. All 42 patients had clinical follow-up information and were evaluated for survival. Sp1 protein was aberrantly overexpressed in a subset of primary pancreatic adenocarcinoma. These tumors all developed metastasis, whereas none of the primary tumors without lymph node metastasis showed Sp1 overexpression. Statistically, Sp1 overexpression was associated with higher stage, higher grade, and lymph node metastasis (P < 0.001, P = 0.036, and P < 0.0001, respectively). Additionally, patients of this subset had a much shorter overall survival than patients without Sp1 overexpression, as evidenced by Kaplan-Meier plots and the log-rank test (P = 0.002). The 5-year overall survival rate was 19% in patients with Sp1 overexpression, compared with 55% in patients without Sp1 overexpression. The median survival was only 13 months for patients with Sp1 overexpression, compared with 65 months for patients without Sp1 overexpression. In conclusion, Sp1 is a new biomarker that identifies a subset of pancreatic ductal adenocarcinoma with aggressive clinical behavior. It can be used at initial diagnosis of pancreatic adenocarcinoma to identify patients with an increased probability of cancer metastasis and much shortened overall survival.
Similar articles
- Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma.
Hang J, Hu H, Huang J, Han T, Zhuo M, Zhou Y, Wang L, Wang Y, Jiao F, Wang L. Hang J, et al. Oncotarget. 2016 May 10;7(19):28207-17. doi: 10.18632/oncotarget.8593. Oncotarget. 2016. PMID: 27057636 Free PMC article. - Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H, Yang Z, Liu Z, Miao X, Yang L, Li D, Zou Q, Yuan Y. Yao H, et al. Cancer Biomark. 2016;17(4):397-404. doi: 10.3233/CBM-160655. Cancer Biomark. 2016. PMID: 27689616 - Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J, Liu S, Xu Y, Wang C, Lin Z, Qin Y, Liu S. Piao J, et al. Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003. Epub 2014 Nov 5. Exp Mol Pathol. 2015. PMID: 25445504 - Expression of specificity protein transcription factors in pancreatic cancer and their association in prognosis and therapy.
Sankpal UT, Maliakal P, Bose D, Kayaleh O, Buchholz D, Basha R. Sankpal UT, et al. Curr Med Chem. 2012;19(22):3779-86. doi: 10.2174/092986712801661077. Curr Med Chem. 2012. PMID: 22725697 Review. - Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis.
Huang C, Xie K. Huang C, et al. Cytokine Growth Factor Rev. 2012 Feb-Apr;23(1-2):25-35. doi: 10.1016/j.cytogfr.2012.01.003. Epub 2012 Feb 16. Cytokine Growth Factor Rev. 2012. PMID: 22342309 Free PMC article. Review.
Cited by
- Salvia ceratophylla L. from South of Jordan: new insights on chemical composition and biological activities.
Abu-Darwish MS, Cabral C, Ali Z, Wang M, Khan SI, Jacob MR, Jain SK, Tekwani BL, Zulfiqar F, Khan IA, Taifour H, Salgueiro L, Efferth T. Abu-Darwish MS, et al. Nat Prod Bioprospect. 2020 Oct;10(5):307-316. doi: 10.1007/s13659-020-00259-9. Epub 2020 Aug 27. Nat Prod Bioprospect. 2020. PMID: 32852722 Free PMC article. - Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: role of Sp transcription factors and microRNA-27a:ZBTB10.
Mertens-Talcott SU, Noratto GD, Li X, Angel-Morales G, Bertoldi MC, Safe S. Mertens-Talcott SU, et al. Mol Carcinog. 2013 Aug;52(8):591-602. doi: 10.1002/mc.21893. Epub 2012 Mar 7. Mol Carcinog. 2013. PMID: 22407812 Free PMC article. - Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.
Hurtado M, Sankpal UT, Kaba A, Mahammad S, Chhabra J, Brown DT, Gurung RK, Holder AA, Vishwanatha JK, Basha R. Hurtado M, et al. Cell Physiol Biochem. 2018;51(4):1894-1907. doi: 10.1159/000495715. Epub 2018 Nov 30. Cell Physiol Biochem. 2018. PMID: 30504717 Free PMC article. - Prognostic Value of COX-2, NF-κB, and Sp1 Tissue Expressions in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis.
Renaldi K, Simadibrata M, Rahadiani N, Handjari DR, William A, Sinuraya F, Makmun D. Renaldi K, et al. Turk J Gastroenterol. 2021 Nov;32(11):956-970. doi: 10.5152/tjg.2021.211106. Turk J Gastroenterol. 2021. PMID: 34872897 Free PMC article. - Transcription factors specificity protein and nuclear receptor 4A1 in pancreatic cancer.
Safe S, Shrestha R, Mohankumar K, Howard M, Hedrick E, Abdelrahim M. Safe S, et al. World J Gastroenterol. 2021 Oct 14;27(38):6387-6398. doi: 10.3748/wjg.v27.i38.6387. World J Gastroenterol. 2021. PMID: 34720529 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical